{"title":"有效和处方不足:氯氮平怎么样?","authors":"Helge H O Müller","doi":"10.4081/mi.2017.7193","DOIUrl":null,"url":null,"abstract":"Clinical psychiatry, especially pharmacological-based treatment regimens still face the problem of high rates of partial or non-responders to the various treatment strategies. So in schizophrenia, a serious psychiatric disease with regard to overall impairment of patients up to three-quarters will experience a relapse after their first episode and one-fifth is facing long-term symptoms often leading to disability and dramatically reduced quality of life and psychosocial outcome.","PeriodicalId":44029,"journal":{"name":"Mental Illness","volume":"9 2","pages":"7193"},"PeriodicalIF":9.0000,"publicationDate":"2017-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/mi.2017.7193","citationCount":"1","resultStr":"{\"title\":\"Effective and underprescribed: what about clozapine?\",\"authors\":\"Helge H O Müller\",\"doi\":\"10.4081/mi.2017.7193\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Clinical psychiatry, especially pharmacological-based treatment regimens still face the problem of high rates of partial or non-responders to the various treatment strategies. So in schizophrenia, a serious psychiatric disease with regard to overall impairment of patients up to three-quarters will experience a relapse after their first episode and one-fifth is facing long-term symptoms often leading to disability and dramatically reduced quality of life and psychosocial outcome.\",\"PeriodicalId\":44029,\"journal\":{\"name\":\"Mental Illness\",\"volume\":\"9 2\",\"pages\":\"7193\"},\"PeriodicalIF\":9.0000,\"publicationDate\":\"2017-10-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4081/mi.2017.7193\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mental Illness\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/mi.2017.7193\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mental Illness","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/mi.2017.7193","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Effective and underprescribed: what about clozapine?
Clinical psychiatry, especially pharmacological-based treatment regimens still face the problem of high rates of partial or non-responders to the various treatment strategies. So in schizophrenia, a serious psychiatric disease with regard to overall impairment of patients up to three-quarters will experience a relapse after their first episode and one-fifth is facing long-term symptoms often leading to disability and dramatically reduced quality of life and psychosocial outcome.